-

SK Capital Partners Appoints John Novak as Head of Business Development

NEW YORK--(BUSINESS WIRE)--SK Capital Partners (“SK Capital”), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, announced today that John Novak has joined the firm as a Managing Director and Head of Business Development. In this position, Mr. Novak will play a leading role in SK Capital’s efforts to identify, prioritize, and execute new investment opportunities across its core sectors, working closely with the firm’s investment teams to support SK Capital’s continued growth.

Mr. Novak brings more than two decades of experience in private equity and investment banking, with a particular focus on building strategic relationships across the industry and sourcing attractive investment opportunities. Prior to joining SK Capital, Mr. Novak was a Managing Director at Paine Schwartz Partners, where he most recently led business development and capital markets efforts with a focus on overseeing and cultivating a pipeline of new investment opportunities. Prior to Paine Schwartz Partners, Mr. Novak held roles at Swander Pace Capital and Banc of America Securities.

“I am excited to join SK Capital as Head of Business Development and look forward to working alongside the firm’s talented team to help drive continued growth and success,” said Mr. Novak.

Mario Toukan, Managing Director at SK Capital Partners, commented, “John has a proven track record of building strong relationships and identifying compelling opportunities that align closely with SK Capital’s investment strategy. His experience, energy, and connectivity make him a valuable addition to the team as we continue to expand our platform and invest in businesses where we can drive transformative growth.”

About SK Capital:
SK Capital is a private investment firm with a disciplined focus on the specialty materials, ingredients, and life sciences sectors. The Firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $12 billion annually, employs more than 25,000 people globally, and operates more than 200 plants in over 30 countries. The Firm currently has approximately $9 billion in assets under management. For more information, please visit www.skcapitalpartners.com.

Contacts

Jeremy Milner
Gregory FCA
jmilner@gregoryfca.com
(401) 862-9422

SK Capital Partners


Release Summary
SK Capital Partners appoints John Novak as Head of Business Development.
Release Versions

Contacts

Jeremy Milner
Gregory FCA
jmilner@gregoryfca.com
(401) 862-9422

More News From SK Capital Partners

Valtris Specialty Chemicals Announces New Chief Human Resources Officer

INDEPENDENCE, Ohio--(BUSINESS WIRE)--Valtris Specialty Chemicals, a leading global manufacturer of a comprehensive portfolio of specialty additives, announced today the appointment of Clint Shephard as the company’s new Chief Human Resources Officer. Mr. Shephard will play a key role in leading the company’s global talent strategy. Mr. Shephard will be based in the company’s new office in Midland, Michigan. Mr. Shephard most recently served as Senior Director of Human Resources at Myers Industr...

SK Capital Partners Completes the Sale of Phoenix Flavors & Fragrances to Turpaz Industries

NORWOOD, N.J.--(BUSINESS WIRE)--Affiliates of funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the material sciences, specialty ingredients, and life sciences sectors, announced today that it has completed the sale of Phoenix Flavors & Fragrances Inc. (“Phoenix” or the “Company”) to Turpaz Industries Ltd (TLV: TRPZ), a global developer, manufacturer, and marketer of specialty fragrance, flavor, and natural ingredient solutions for consumer and in...

SK Capital Partners Completes Sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG

NEW YORK--(BUSINESS WIRE)--Affiliates of funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the life sciences, specialty materials, and ingredients sectors announced today they have completed the sale of Noramco, Extractas Biosciences, and Purisys of the Noramco Group (“Noramco” or the “Company”) to Siegfried Holding AG (SIX: SFZN; “Siegfried”), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry....
Back to Newsroom